<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957436</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1105 GETUG AFU-21</org_study_id>
    <nct_id>NCT01957436</nct_id>
  </id_info>
  <brief_title>A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer</brief_title>
  <acronym>PEACE1</acronym>
  <official_title>A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase III study to compare the clinical benefit of androgen
      deprivation therapy (+ docetaxel) with or without local radiotherapy with or without
      abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients can be randomize in the trial after his consent form has been signed, and
      after all inclusion and non-inclusion criteria have been checked.

      The randomisation will result in the allocation of arm A (ADT +docetaxel), arm B (ADT
      +docetaxel +Abiraterone), arm C (ADT +docetaxel +radiotherapy) or arm D (ADT +docetaxel
      +Abiraterone +radiotherapy) in a 1:1:1:1 ratio.

      The randomization will be stratified (by minimization) according to:

        -  enrolment center,

        -  performance status (0 vs. 1-2)

        -  disease extent: lymph nodes only vs. bone (with or without lymph nodes) vs. presence of
           visceral metastases.

      CRPC is defined by cancer progression (either a confirmed PSA rise or a radiological
      progression) with serum testosterone being at castrated levels (&lt;0.50 ng/mL).

      When the CRPC stage is reached, castration (either LHRH agonist or LHRH antagonist) will be
      maintained in all patients.

      Investigators will be free to manage patients reaching CRPC at their discretion (using for
      example docetaxel, zoledronic acid, denosumab, sipuleucel-T, radium-223, cabazitaxel, etc)
      according to local uses and guidelines.

      Abiraterone may be used in arm A and C if abiraterone has become the standard treatment for
      CRPC when this stage is reached.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 13, 2013</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>5.5 years after the first inclusion</time_frame>
    <description>Overall and progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>8 months</time_frame>
    <description>The PSA response rate will be defined by an undetectable serum PSA level at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective correlative study of PSA response/progression at 8 months after initation of ADT</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>5.5 years</time_frame>
    <description>will be evaluated by questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next skeletal-related event</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to chemotherapy for CRPC</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to severe local symptoms</measure>
    <time_frame>5.5 years</time_frame>
    <description>The time to severe local symptoms (grade 3 and 4 events) related to tumor progression and/or radiotherapy long term side effects will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the study treatment</measure>
    <time_frame>5.5 years</time_frame>
    <description>Toxicity (with a specific focus on the use of long-term low-dose steroids) will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The radiological progression-free survival</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bone mineral density</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of biomarkers with outcome</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1173</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>androgen deprivation therapy + docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A + radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B + radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone acetate</intervention_name>
    <description>abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Androgen Deprivation Therapy</intervention_name>
    <description>The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>6 cycles at 75mg/m²/cycle, one cycle every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate,

          2. Metastatic disease documented by a positive bone scan (any technique) or CT scan or an
             MRI. For patients with nodal metastases only, only patients with extra-pelvic enlarged
             lymph nodes (lymph nodes located above the iliac bifurcation) can be included if they
             have either:

             o At least one extra-pelvic lymph node ≥ 2 cm or extra-pelvic lymph node (s) ≥ 1 cm if
             the patients also have at least one pelvic lymph node ≥ 2 cm

          3. Patients with ECOG ≤ 1 (patient with PS 2 due to bone pain can be accrued in the
             trial),

          4. Life expectancy of at least 6 months,

          5. Male aged ≥ 18 years old and ≤80 years old ,

          6. Hematology values:

               -  Hemoglobin ≥ 10.0 g/dL,

               -  Platelet count ≥ 100,000/mL,

               -  Neutrophil ≥ 1500 cells/mm3

          7. Biochemistry values:

               -  Renal function: Serum creatinine &lt; 1.5 x ULN or a calculated creatinine clearance
                  ≥ 60 mL/min,

               -  Serum potassium ≥ 4 mmol/L,

               -  Liver function:

                    -  Serum bilirubin ≤ 1.5 x ULN (except for patients with documented Gilbert's
                       disease),

                    -  AST and ALT ≤ 1.5 x ULN (and ≤ 5 ULN in case of liver metastases),

               -  ALK-P ≤ 2.5 x ULN (in case of bone metastasis, ALK-P&lt;1000U/L if bilirubin is
                  normal)

          8. Patients must have received ADT for a maximum of 3 months before randomization and
             there must be a minimum of 6 weeks between the start of ADT and the start of
             Docetaxel,

          9. Patients willing and clinically fit to receive Docetaxel which is defined by the
             following :

               -  Patients respecting all inclusion and exclusion criteria And

               -  Patients with no contraindication to docetaxel according to the SmPC of the drug
                  And

               -  Patients presenting all medical requirements to receive docetaxel according to
                  the investigator's opinion.

         10. Patients might have received previous radiation therapy directed to bone lesions,

         11. Patients able to take oral medication,

         12. Patients who have received the information sheet and signed the informed consent form,

         13. Male patients who will receive Docetaxel and/or Abiraterone acetate and have partners
             of childbearing potential and/or pregnant partners must use a method of birth control
             in addition to an adequate barrier protection (condoms) as determined to be acceptable
             by the study doctor during the treatment period and for 4 weeks after the last dose of
             abiraterone acetate and/or for 6 months after the last dose of Docetaxel

         14. Patients must be willing and able to comply with scheduled visits, treatment plan,
             laboratory tests and other study procedures,

         15. Patients with a public or a private health insurance coverage, according to local laws
             for participation in clinical trials.

        Exclusion Criteria:

          1. Patients with previous definitive local treatment directed to the prostate primary
             cancer (radiotherapy, brachytherapy, radical prostatectomy, ultrasound, cryotherapy,
             or other). A previous trans-urethral resection of the prostate (TURP) and previous
             local treatments of metastase are allowed,

          2. Prior cytotoxic chemotherapy or biological therapy for the treatment of prostate
             cancer,

          3. Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg
             prednisone/prednisolone twice daily,

          4. Active infection or other medical condition for which prednisone/prednisolone
             (corticosteroid) use would be contra-indicated,

          5. Previously treated with ketoconazole for prostate cancer for more than 7 days,

          6. Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4
             weeks of randomization,

          7. Hypertension not controlled by an anti-hypertensive treatment (systolic BP ≥ 160 mmHg
             or diastolic BP ≥ 95 mmHg; 3 consecutive measures taken 5 minutes apart),

          8. Severe or moderate hepatic impairment (Child - Pugh class C or B)

          9. Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert's
             disease),

         10. History of pituitary or adrenal dysfunction,

         11. Clinically known significant heart disease as evidenced by myocardial infarction, or
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New
             York Heart association (NYHA) Class II-IV heart disease or cardiac ejection fraction
             measurement of &lt; 50% at baseline,

         12. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy,

         13. Patient with unstable pulmonary disease (eg. Pulmonary embolism)

         14. Pathological finding consistent with small cell carcinoma of the prostate,

         15. History of malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of
             recurrence within 24 months,

         16. Known allergies, hypersensitivity or intolerance to the study drugs or excipients or
             docetaxel

         17. Administration of an investigational therapeutic within 30 days of randomization,

         18. Patients already included in another therapeutic trial involving an experimental drug
             (patient in a non-experimental trial with no modification of the patient's care can be
             included),

         19. Patients with significantly altered mental status prohibiting the understanding of the
             study or with psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule or any
             condition which, in the opinion of the investigator, would preclude participation in
             this trial. Those conditions should be discussed with the patient before registration
             in the trial,

         20. Individual deprived of liberty or placed under the authority of a tutor.

         21. Patients with impaired vision should undergo a prompt and complete ophtalmologic
             examination.

             Patients with Cystoid Macular Oeadema cannot be included due to a potential risk of
             deterioration associated with docetaxel.

         22. Concomitant use of strong CYP3A4 inhibitors ( clarithromyin, indinavir, nefazodone,
             nelfinavir, ritonavir, saquinavir, telithromycin.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim FIZAZI, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto BOSSI, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris - Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet Erasme- Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk - Campus Vercruysselaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Louvain</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'Ouest</name>
      <address>
        <city>ANGERS Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Générale d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de la Baie</name>
      <address>
        <city>Avranches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Pays Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Pierre Curie</name>
      <address>
        <city>Beuvry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Leman</name>
      <address>
        <city>Contamine Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SERA</name>
      <address>
        <city>Contamine Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leonard de Vinci</name>
      <address>
        <city>Dechy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François LECLERC</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Marguerite</name>
      <address>
        <city>Hyères</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La ROCHE sur YON</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Timone</name>
      <address>
        <city>MARSEILLE Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes Cedex 2</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>NIMES Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Orléans la source</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital TENON</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chic Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>RENNES Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU ST ETIENNE - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>44270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Gregoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie del'Ouest - site René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTRE DE CANCEROLOGIE Paris Nord</name>
      <address>
        <city>Sarcelles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>St PRIEST EN JAREZ</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg Oncologie Libérale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Leman</name>
      <address>
        <city>Thonon-les-bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Toulon - La Seyne sur Mer - Hôpital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>TOULOUSE Cedex 3</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>TOULOUSE Cedex</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie Saint Yves</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTITUT GUSTAVE ROUSSY, Cancer Campus, Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide and Meath incorporating National Children's hospital department</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Camillo Forlanini Hospitals</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sc Radiotherapy Center Cluj SRL</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 OCTUBRE</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Althaia</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'Hospital Clinico Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'Parc Tauli Sabadell Hospital Universitari</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Dr. Henri Dubois-Ferrière Dinu Lipatti</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic hormone-naive</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>abiraterone acetate</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

